BLUE: bluebird bio, Inc Price/Earnings to Growth Ratio
High margins and pricing power of the gene therapy pioneer bluebird bio, Inc. (BLUE) support growth, which is why a PEG ratio chart is available in the GURU.Markets system, where this metric equals 0.00. However, the commercialization of anemia treatments and the transition to robotic bioreactors to eliminate defects create certain operational risks, impacting the current market value of the assets.
bluebird bio (BLUE) - metric breakdowns and financial figures
- current quotes and average value forecast:
- market capitalization information:
- issuer book value statistics:
- debt obligations and liquidity statistics:
Debt to Equity Ratio bluebird bio, Inc.|BLUE - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital bluebird bio|BLUE - Company Aggregate Debts|Debt to Book Capitalization Ratio bluebird bio, Inc|BLUE - Company Long-Term Debts|Short-Term Debt Volume bluebird bio|Immediate Liquidity bluebirdbio.com
- net income and valuation ratios data:
BLUE - Net Income|Expected Net Income bluebird bio, Inc.|BLUE - P/E Multiple|Market Cap to Projected Earnings bluebirdbio.com|BLUE - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation bluebird bio, Inc|BLUE - Operating profit EBITDA|Net earnings per share for the last 12 months bluebird bio|BLUE - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months bluebirdbio.com|BLUE - Earnings growth in current year|Net earnings per share growth forecast for next year bluebird bio, Inc.
- total revenue and sales volume data:
General company analysis:Bluebird Bio BLUE
The stability of bluebird bio, Inc. (BLUE) depends on international patent protection and the uninterrupted import of biocomponents amid geopolitical pressure. The PEG ratio compares the business's market value with its earnings growth rate, allowing investors to identify an undervalued asset when the value is below one, which is clearly reflected in the price action of this chart.
Competing companies
PEG Multiple Tempus (TEM)|PEG Multiple QGEN (Qiagen NV)|Growth-Adjusted Market Cap to Net Income Ionis (IONS)|repligen.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Avidity|CRSP (CRISPR Therapeutics Corp) - Price/Earnings to Growth Multiple|GeneDx Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ultragenyx|Price to Earnings Adjusted for Growth Rate beamtx.com BEAM|Price/Earnings to Growth Multiple SRPT (Sarepta Therapeutics, Inc.)|TWST - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio 10x TXG|Company Value to Earnings Growth Ratio NTLA (Intellia)|Stoke Corp - PEG Multiple|BLFS: Price/Earnings to Growth Ratio|WVE: PEG Multiple|Price to Earnings Adjusted for Growth Rate Maze Tx (MAZE)|Price/Earnings to Growth Ratio Sionna Therapeutics|Growth-Adjusted P/E Ratio PRME (Prime Medicine Corp)|PEG Multiple TSHA|PEG Multiple uniqure.com (QURE)|Price/Earnings to Growth Ratio MeiraGTx PLC MGTX|Growth-Adjusted Payback Ratio RGNX|solidbio.com - PEG Multiple|OCGN (Ocugen Pharma) - Growth-Adjusted P/E Ratio|PACB: PEG Multiple|Benitec Biopharma (BNTC) - PEG Multiple|DSGN (Design Therapeutics Inc) - PEG Multiple|Rocket Pharmaceuticals, Inc. (RCKT) - Growth-Adjusted Market Cap to Net Income|FDMT - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio LXEO (Lexeo)|Price/Earnings to Growth Ratio korrobio.com KRRO|Growth-Adjusted Market Cap to Net Income Editas Medicine, Inc. (EDIT)|SLN - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income ProQR PRQR|CDXS: PEG Multiple|Price to Net Income Growth Ratio Sangamo BioSciences SGMO|Price/Earnings to Growth Ratio Nautilus Bio|MGX (Metagenomi, Inc.) - Company Value to Earnings Growth Ratio|PEG Multiple DTIL|Generation Bio - Growth-Adjusted P/E Ratio|PEG Multiple BOLD (Boundless Bio Inc.)|Growth-Adjusted Payback Ratio XCUR|Imunon Inc - PEG Multiple|PHIO (phiopharma.com) - Growth-Adjusted P/E Ratio|MBIO (mustangbio.com) - Price/Earnings to Growth Multiple|Growth-Adjusted P/E Ratio RNAZ|BNGO (Bionano) - PEG Multiple|PEG Multiple Applied DNA Corp|PEG Multiple IPA|Omega Therapeutics (OMGA) - Price to Net Income Growth Ratio|PEG Multiple OMIC (Singular Genomics Systems Inc)|Price to Net Income Growth Ratio Regulus Therapeutics Inc|SYRS - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio TBIO (Codex DNA)|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income
